Neuron-specific enolase (NSE), enriched in neurons and peripheral neuroendocrine cells, is a clinically relevant biomarker for staging, monitoring treatment, and predicting relapse in small cell lung cancer (SCLC) [60]. This evidence concerns the gene ENO2 and small cell lung carcinoma.